- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
International Journal of Hypertension
Volume 2011 (2011), Article ID 232683, 5 pages
Vascular Damage in Kidney Disease: Beyond Hypertension
1Basic Pathology Department, Laboratory of Experimental Nephrology, Universidade Federal do Paraná, 80531-980 Curitiba, PR, Brazil
2Center for Health and Biological Sciences, Pontifícia Universidade Católica do Paraná, Rua Imaculada Conceição, 1155, 80215-901 Curitiba, PR, Brazil
Received 20 December 2010; Revised 30 June 2011; Accepted 3 July 2011
Academic Editor: Cesare Cuspidi
Copyright © 2011 Andréa E. M. Stinghen and Roberto Pecoits-Filho. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- M. El Nahas, “Cardio-kidney-damage: a unifying concept,” Kidney International, vol. 78, no. 1, pp. 14–18, 2010.
- A. A. House, M. Haapio, J. Lassus, R. Bellomo, and C. Ronco, “Therapeutic strategies for heart failure in cardiorenal syndromes,” American Journal of Kidney Diseases, vol. 56, no. 4, pp. 759–773, 2010.
- P. Stenvinkel, J. J. Carrero, J. Axelsson, B. Lindholm, O. Heimburger, and Z. Massy, “Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle?” Clinical Journal of the American Society of Nephrology, vol. 3, no. 2, pp. 505–521, 2008.
- P. Stenvinkel, “Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease,” Journal of Internal Medicine, vol. 268, no. 5, pp. 456–467, 2010.
- B. K. Meijers, K. Claes, B. Bammens et al., “p—and cardiovascular risk in mild-to-moderate kidney disease,” Clinical Journal of the American Society of Nephrology, vol. 5, no. 7, pp. 1182–1189, 2010.
- R. J. Glassock, “Uremic toxins: what are they? An integrated overview of pathobiology and classification,” Journal of Renal Nutrition, vol. 18, no. 1, pp. 2–6, 2008.
- J. Himmelfarb, “Uremic toxicity, oxidative stress, and hemodialysis as renal replacement therapy,” Seminars in Dialysis, vol. 22, no. 6, pp. 636–643, 2009.
- R. Vanholder, S. Van Laecke, and G. Glorieux, “What is new in uremic toxicity?” Pediatric Nephrology, vol. 23, no. 8, pp. 1211–1221, 2008.
- R. Vanholder, R. De Smet, G. Glorieux et al., “Review on uremic toxins: classification, concentration, and interindividual variability,” Kidney International, vol. 63, no. 5, pp. 1934–1943, 2003.
- R. Vanholder, A. Argiles, U. Baurmeister et al., “Uremic toxicity: present state of the art,” International Journal of Artificial Organs, vol. 24, no. 10, pp. 695–725, 2001.
- J. Malyszko, “Mechanism of endothelial dysfunction in chronic kidney disease,” Clinica Chimica Acta, vol. 411, no. 19-20, pp. 1412–1420, 2010.
- D. Fliser, “Perspectives in renal disease progression: the endothelium as a treatment target in chronic kidney disease,” Journal of Nephrology, vol. 23, no. 4, pp. 369–376, 2010.
- G. Cohen, G. Glorieux, P. Thornalley et al., “Review on uraemic toxins III: recommendations for handling uraemic retention solutes in vitro—towards a standardized approach for research on uraemia,” Nephrology Dialysis Transplantation, vol. 22, no. 12, pp. 3381–3390, 2007.
- M. S. Segal, C. Baylis, and R. J. Johnson, “Endothelial health and diversity in the kidney,” Journal of the American Society of Nephrology, vol. 17, no. 2, pp. 323–324, 2006.
- J. A. Diaz-Buxo and H. F. Woods, “Protecting the endothelium: a new focus for management of chronic kidney disease,” Hemodialysis International, vol. 10, no. 1, pp. 42–48, 2006.
- L. Dou, N. Jourde-Chiche, V. Faure et al., “The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells,” Journal of Thrombosis and Haemostasis, vol. 5, no. 6, pp. 1302–1308, 2007.
- S. Bro, J. F. Bentzon, E. Falk, C. B. Andersen, K. Olgaard, and L. B. Nielsen, “Chronic renal failure accelerates atherogenesis in apolipoprotein E-deficient mice,” Journal of the American Society of Nephrology, vol. 14, no. 10, pp. 2466–2474, 2003.
- M. Buzello, J. Törnig, J. Faulhaber, H. Ehmke, E. Ritz, and K. Amann, “The apolipoprotein E knockout mouse: a model documenting accelerated atherogenesis in uremia,” Journal of the American Society of Nephrology, vol. 14, no. 2, pp. 311–316, 2003.
- P. Brunet, B. Gondouin, A. Duval-Sabatier, L. Dou, C. Cerini, F. Dignat-George, et al., “Does uremia cause vascular dysfunction?” Kidney and Blood Pressure Research, vol. 34, no. 4, pp. 284–290, 2011.
- S. Zieman and D. Kass, “Advanced glycation end product cross-linking: pathophysiologic role and therapeutic target in cardiovascular disease,” Congestive Heart Failure, vol. 10, no. 3, pp. 144–151, 2004.
- P. M. Vanhoutte, M. Feletou, and S. Taddei, “Endothelium-dependent contractions in hypertension,” British Journal of Pharmacology, vol. 144, no. 4, pp. 449–458, 2005.
- D. Fliser, F. Kronenberg, J. T. Kielstein et al., “Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study,” Journal of the American Society of Nephrology, vol. 16, no. 8, pp. 2456–2461, 2005.
- R. H. Boger, S. M. Bode-Boger, K. Sydow, D. D. Heistad, and S. R. Lentz, “Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 6, pp. 1557–1564, 2000.
- R. Vanholder, U. Baurmeister, P. Brunet, G. Cohen, G. Glorieux, and J. Jankowski, “A bench to bedside view of uremic toxins,” Journal of the American Society of Nephrology, vol. 19, no. 5, pp. 863–870, 2008.
- R. Vanholder, S. van Laecke, and G. Glorieux, “The middle-molecule hypothesis 30 years after: lost and rediscovered in the universe of uremic toxicity?” Journal of Nephrology, vol. 21, no. 2, pp. 146–160, 2008.
- J. R. Stubbs and J. B. Wetmore, “Does it matter how parathyroid hormone levels are suppressed in secondary hyperparathyroidism?” Seminars in Dialysis, vol. 24, no. 3, pp. 298–306, 2011.
- K. R. Neves, F. G. Graciolli, L. M. dos Reis et al., “Vascular calcification: contribution of parathyroid hormone in renal failure,” Kidney International, vol. 71, no. 12, pp. 1262–1270, 2007.
- A. E. Stinghen, S. M. Goncalves, E. G. Martines et al., “Increased plasma and endothelial cell expression of chemokines and adhesion molecules in chronic kidney disease,” Nephron Clinical Practice, vol. 111, no. 2, pp. c117–c126, 2009.
- A. B. Hauser, I. R. Azevedo, S. Goncalves, A. Stinghen, C. Aita, and R. Pecoits-Filho, “Sevelamer carbonate reduces inflammation and endotoxemia in an animal model of uremia,” Blood Purification, vol. 30, no. 3, pp. 153–158, 2010.
- S. Goncalves, R. Pecoits-Filho, S. Perreto et al., “Associations between renal function, volume status and endotoxaemia in chronic kidney disease patients,” Nephrology Dialysis Transplantation, vol. 21, no. 10, pp. 2788–2794, 2006.
- B. Aline, A. E. M. S. Hauser, M. G. Simone, S. Bucharles, and R. Pecoits-Filho, “A gut feeling on endotoxemia: causes and consequences in chronic kidney disease,” Nephron Clinical Practice, vol. 118, no. 2, pp. c165–c172, 2010.
- T. Gunthner, V. Jankowski, A. Kretschmer et al., “Endothelium and vascular smooth muscle cells in the context of uremia,” Seminars in Dialysis, vol. 22, no. 4, pp. 428–432, 2009.
- P. Stenvinkel and T. J. Ekstrom, “Epigenetics—a helpful tool to better understand processes in clinical nephrology?” Nephrology Dialysis Transplantation, vol. 23, no. 5, pp. 1493–1496, 2008.
- P. Stenvinkel, M. Karimi, S. Johansson et al., “Impact of inflammation on epigenetic DNA methylation—a novel risk factor for cardiovascular disease?” Journal of Internal Medicine, vol. 261, no. 5, pp. 488–499, 2007.
- D. Ingrosso, A. Cimmino, A. F. Perna et al., “Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteinaemia in patients with uraemia,” The Lancet, vol. 361, no. 9370, pp. 1693–1699, 2003.
- Y. S. Huang, Y. F. Zhi, and S. R. Wang, “Hypermethylation of estrogen receptor-α gene in atheromatosis patients and its correlation with homocysteine,” Pathophysiology, vol. 16, no. 4, pp. 259–265, 2009.
- J. Yi-Deng, S. Tao, Z. Hui-Ping et al., “Folate and ApoE DNA methylation induced by homocysteine in human monocytes,” DNA and Cell Biology, vol. 26, no. 10, pp. 737–744, 2007.
- G. Zaza, P. Pontrelli, G. Pertosa et al., “Dialysis-related systemic microinflammation is associated with specific genomic patterns,” Nephrology Dialysis Transplantation, vol. 23, no. 5, pp. 1673–1681, 2008.
- N. Karin, “The multiple faces of CXCL12 (SDF-1α) in the regulation of immunity during health and disease,” Journal of Leukocyte Biology, vol. 88, no. 3, pp. 463–473, 2010.
- P. Rueda, K. Balabanian, B. Lagane et al., “The CXCL12γ chemokine displays unprecedented structural and functional properties that make it a paradigm of chemoattractant proteins,” PLoS ONE, vol. 3, no. 7, Article ID e2543, 2008.
- F. Barbieri, A. Bajetto, C. Porcille, A. Pattarozzi, G. Schettini, and T. Florio, “Role of stromal cell-derived factor 1 (SDF1/CXCL12) in regulating anterior pituitary function,” Journal of Molecular Endocrinology, vol. 38, no. 3-4, pp. 383–389, 2007.
- S. Ghadge, S. Muhlstedt, C. Ozcelik, and M. Bader, “SDF-1α as a therapeutic stem cell homing factor in myocardial infarction,” Pharmacology & Therapeutics, vol. 129, pp. 97–108, 2011.
- K. E. Jie, M. A. Zaikova, M. W. Bergevoet et al., “Progenitor cells and vascular function are impaired in patients with chronic kidney disease,” Nephrology Dialysis Transplantation, vol. 25, no. 6, pp. 1875–1882, 2010.
- A. Kottgen, “Genome-wide association studies in nephrology research,” American Journal of Kidney Diseases, vol. 56, no. 4, pp. 743–758, 2010.
- V. O. Shah, E. A. Dominic, P. Moseley et al., “Hemodialysis modulates gene expression profile in skeletal muscle,” American Journal of Kidney Diseases, vol. 48, no. 4, pp. 616–628, 2006.